Cargando…
Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia
Objectives: To determine whether drug-induced lymphocytopenia is associated with drug retention rates of JAKi (tofacitinib or baricitinib) in rheumatoid arthritis (RA) patients. Methods: Patients with RA who were initiated with tofacitinib (n = 38) or baricitinib (n = 74) between July 2015 and July...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381502/ https://www.ncbi.nlm.nih.gov/pubmed/37510940 http://dx.doi.org/10.3390/jcm12144827 |
_version_ | 1785080460086345728 |
---|---|
author | Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Watanabe, Hiroshi Migita, Kiyoshi |
author_facet | Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Watanabe, Hiroshi Migita, Kiyoshi |
author_sort | Temmoku, Jumpei |
collection | PubMed |
description | Objectives: To determine whether drug-induced lymphocytopenia is associated with drug retention rates of JAKi (tofacitinib or baricitinib) in rheumatoid arthritis (RA) patients. Methods: Patients with RA who were initiated with tofacitinib (n = 38) or baricitinib (n = 74) between July 2015 and July 2022 and continued for at least 4 months were enrolled in this study. Absolute lymphocyte count (ALC) value was obtained pre-treatment and monthly after initiation of JAKi (up to 4 months). Associations between ALC nadir at an early phase (up to 4 months) from JAKi initiation and drug retention rates were analysed. Results: 112 patients (87 females; age, 71.2 ± 14.0 years; disease duration, 9.2 ± 10.5 months; DAS28-CRP, 3.60 ± 1.12; DAS28-ESR, 4.43 ± 1.29; CDAI, 17.9 ± 12.9; C-reactive protein, 3.07 ± 3.43 mg/dL; and lymphocyte count, 1361.9 ± 538.7 per μL) treated with tofacitinib or baricitinib were retrospectively analysed. Lymphocytopenia (>10% decline in lymphocyte count to pre-treatment basal levels) was observed in a quarter of RA patients treated with JAKi (tofacitinib; 16 baricitinib; 14). RA patients with lymphopenia were associated with the lower drug retention rates of tofacitinib compared to those without lymphocytopenia. The reduced drug retention rates in patients with lymphocytopenia were attributed to the discontinuation of tofacitinib due to AEs. Whereas lymphocytopenia was not associated with lower drug retention rates of baricitinib. Pre-treatment absolute lymphocyte counts did not affect the drug retention rates of JAKi in patients with RA. Conclusions: These findings suggest that lymphopenia during the first 4 months from the initiation of JAKi is associated with reduced drug retention rates in patients with RA due to AEs, which is exclusively associated with the use of tofacitinib. |
format | Online Article Text |
id | pubmed-10381502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103815022023-07-29 Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Watanabe, Hiroshi Migita, Kiyoshi J Clin Med Article Objectives: To determine whether drug-induced lymphocytopenia is associated with drug retention rates of JAKi (tofacitinib or baricitinib) in rheumatoid arthritis (RA) patients. Methods: Patients with RA who were initiated with tofacitinib (n = 38) or baricitinib (n = 74) between July 2015 and July 2022 and continued for at least 4 months were enrolled in this study. Absolute lymphocyte count (ALC) value was obtained pre-treatment and monthly after initiation of JAKi (up to 4 months). Associations between ALC nadir at an early phase (up to 4 months) from JAKi initiation and drug retention rates were analysed. Results: 112 patients (87 females; age, 71.2 ± 14.0 years; disease duration, 9.2 ± 10.5 months; DAS28-CRP, 3.60 ± 1.12; DAS28-ESR, 4.43 ± 1.29; CDAI, 17.9 ± 12.9; C-reactive protein, 3.07 ± 3.43 mg/dL; and lymphocyte count, 1361.9 ± 538.7 per μL) treated with tofacitinib or baricitinib were retrospectively analysed. Lymphocytopenia (>10% decline in lymphocyte count to pre-treatment basal levels) was observed in a quarter of RA patients treated with JAKi (tofacitinib; 16 baricitinib; 14). RA patients with lymphopenia were associated with the lower drug retention rates of tofacitinib compared to those without lymphocytopenia. The reduced drug retention rates in patients with lymphocytopenia were attributed to the discontinuation of tofacitinib due to AEs. Whereas lymphocytopenia was not associated with lower drug retention rates of baricitinib. Pre-treatment absolute lymphocyte counts did not affect the drug retention rates of JAKi in patients with RA. Conclusions: These findings suggest that lymphopenia during the first 4 months from the initiation of JAKi is associated with reduced drug retention rates in patients with RA due to AEs, which is exclusively associated with the use of tofacitinib. MDPI 2023-07-21 /pmc/articles/PMC10381502/ /pubmed/37510940 http://dx.doi.org/10.3390/jcm12144827 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Temmoku, Jumpei Miyata, Masayuki Suzuki, Eiji Sumichika, Yuya Saito, Kenji Yoshida, Shuhei Matsumoto, Haruki Fujita, Yuya Matsuoka, Naoki Asano, Tomoyuki Sato, Shuzo Watanabe, Hiroshi Migita, Kiyoshi Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia |
title | Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia |
title_full | Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia |
title_fullStr | Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia |
title_full_unstemmed | Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia |
title_short | Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia |
title_sort | drug retention rates of janus kinase inhibitors in rheumatoid arthritis patients with therapy-induced lymphopenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381502/ https://www.ncbi.nlm.nih.gov/pubmed/37510940 http://dx.doi.org/10.3390/jcm12144827 |
work_keys_str_mv | AT temmokujumpei drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT miyatamasayuki drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT suzukieiji drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT sumichikayuya drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT saitokenji drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT yoshidashuhei drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT matsumotoharuki drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT fujitayuya drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT matsuokanaoki drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT asanotomoyuki drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT satoshuzo drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT watanabehiroshi drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia AT migitakiyoshi drugretentionratesofjanuskinaseinhibitorsinrheumatoidarthritispatientswiththerapyinducedlymphopenia |